DAE HWA Pharmaceutical Co. Ltd (067080) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DAE HWA Pharmaceutical Co. Ltd (067080) has a cash flow conversion efficiency ratio of 0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩314.63 Million ≈ $213.22K USD) by net assets (₩85.06 Billion ≈ $57.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DAE HWA Pharmaceutical Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
DAE HWA Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DAE HWA Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DAE HWA Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DAE HWA Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agenus Inc
NASDAQ:AGEN
|
0.158x |
|
Yunsung F&C Co. Ltd.
KQ:372170
|
-0.111x |
|
HMA AGRO INDUSTRIES ORD (BSE)
NSE:HMAAGRO
|
0.033x |
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
0.004x |
|
Stel Holdings Limited
NSE:STEL
|
0.005x |
|
Info-Tek
TWO:8183
|
0.002x |
|
TONGDAO LIEP.GR. DL-0001
F:6WT
|
N/A |
|
Lalin Property Public Company Limited
BK:LALIN
|
-0.017x |
Annual Cash Flow Conversion Efficiency for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 067080 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩79.14 Billion ≈ $53.63 Million |
₩5.43 Billion ≈ $3.68 Million |
0.069x | -19.40% |
| 2024-12-31 | ₩72.00 Billion ≈ $48.79 Million |
₩6.13 Billion ≈ $4.15 Million |
0.085x | +1155.66% |
| 2023-12-31 | ₩73.23 Billion ≈ $49.63 Million |
₩-590.27 Million ≈ $-400.02K |
-0.008x | -107.81% |
| 2022-12-31 | ₩77.99 Billion ≈ $52.85 Million |
₩8.05 Billion ≈ $5.45 Million |
0.103x | -21.32% |
| 2021-12-31 | ₩79.67 Billion ≈ $53.99 Million |
₩10.45 Billion ≈ $7.08 Million |
0.131x | +270.58% |
| 2020-12-31 | ₩81.98 Billion ≈ $55.56 Million |
₩2.90 Billion ≈ $1.97 Million |
0.035x | +6935.37% |
| 2019-12-31 | ₩79.35 Billion ≈ $53.77 Million |
₩-41.07 Million ≈ $-27.83K |
-0.001x | -100.38% |
| 2018-12-31 | ₩76.88 Billion ≈ $52.10 Million |
₩10.49 Billion ≈ $7.11 Million |
0.136x | -4.30% |
| 2017-12-31 | ₩76.75 Billion ≈ $52.02 Million |
₩10.94 Billion ≈ $7.42 Million |
0.143x | +7.31% |
| 2016-12-31 | ₩66.15 Billion ≈ $44.83 Million |
₩8.79 Billion ≈ $5.96 Million |
0.133x | +233.71% |
| 2015-12-31 | ₩61.06 Billion ≈ $41.38 Million |
₩2.43 Billion ≈ $1.65 Million |
0.040x | -62.31% |
| 2014-12-31 | ₩58.51 Billion ≈ $39.65 Million |
₩6.18 Billion ≈ $4.19 Million |
0.106x | -51.73% |
| 2013-12-31 | ₩62.03 Billion ≈ $42.04 Million |
₩13.57 Billion ≈ $9.20 Million |
0.219x | +132.79% |
| 2012-12-31 | ₩61.39 Billion ≈ $41.60 Million |
₩5.77 Billion ≈ $3.91 Million |
0.094x | +56.14% |
| 2011-12-31 | ₩56.99 Billion ≈ $38.62 Million |
₩3.43 Billion ≈ $2.32 Million |
0.060x | -- |
About DAE HWA Pharmaceutical Co. Ltd
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthriti… Read more